Kim HJ, Karpeh MS: Surgical approaches and outcomes in the treatment of gastric cancer. Semin Radiat Oncol 2002, 12:162–9.MAPK Inhibitor Library PubMedCrossRef 2. Beghelli S, de Manzoni G, Barbi S, Tomezzoli A, Roviello F, Di Gregorio C, Vindigni C, Bortesi L, Parisi A, Saragoni L, Scarpa A, Moore PS: Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 2006, 139:347–56.PubMedCrossRef

3. Fleisher AS, Esteller M, Wang S, Tamura G, Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, Shi YQ, Rhyu MG, Powell SM, James SP, Wilson KT, Herman JG, Meltzer SJ: Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite www.selleckchem.com/HDAC.html instability. Cancer Res 1999, 59:1090–5.PubMed 4. Iacopetta BJ, Soong R, House AK, Hamelin R: Akt activity Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor,

IGFII receptor, and BAX genes. J Pathol 1999, 187:428–32.PubMedCrossRef 5. Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004, 327–49. 6. Wu MS, Lee CW, Shun CT, Wang HP, Lee WJ, Chang MC, Sheu JC, Lin JT: Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer 2000, 27:403–11.PubMedCrossRef 7. Bragantini E, Barbi S, Beghelli S, Moore PS, de Manzoni G, Roviello those F, Tomezzoli A, Vindigni C, Baffa R, Scarpa A: Loss of Fhit expression is associated with poorer survival in gastric cancer but is not an independent prognostic marker. J Cancer Res Clin Oncol 2006, 132:45–50.PubMedCrossRef 8. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins

GJ, Willson JKV, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.PubMedCrossRef 9. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004, 3:772–775.PubMedCrossRef 10. Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. Annu Rev Biochem 1998, 67:481–507.PubMedCrossRef 11. Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002, 296:1655–7.PubMedCrossRef 12. Bader AG, Kang S, Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006, 103:1475–9.PubMedCrossRef 13. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005, 102:802–7.PubMedCrossRef 14. Zhao L, Vogt PK: Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008, 105:2652–7.PubMedCrossRef 15.